Publication of the BE VIVID study results for bimekizumab (Bimzelx) occurred on 2021-01-01, detailing its efficacy and safety profile compared to ustekinumab for moderate to severe plaque psoriasis. This 52-week, multicentre, double-blind study's findings were published in The Lancet.
Background
Bimekizumab, also known by its brand name Bimzelx, is a drug investigated for the treatment of moderate to severe plaque psoriasis. Plaque psoriasis is a chronic autoimmune disease characterized by the rapid buildup of skin cells, leading to thick, red, scaly patches on the skin.
Trial design
The BE VIVID study was a 52-week, multicentre, double-blind clinical trial designed to evaluate the efficacy and safety of bimekizumab. The study enrolled adult subjects diagnosed with moderate to severe chronic plaque psoriasis. Its design included comparisons against both placebo and an active comparator, which was ustekinumab, to assess bimekizumab's performance in this patient population.
Key results
The published results from the BE VIVID study detailed the efficacy and safety profile of bimekizumab when compared to ustekinumab for the treatment of moderate to severe plaque psoriasis. The publication specifically highlighted the findings from the comprehensive 52-week evaluation period, providing insights into the drug's long-term performance.
What this means
The publication of the BE VIVID study results provides important comparative data on bimekizumab's performance against ustekinumab, a recognized treatment for moderate to severe plaque psoriasis. Clinicians and researchers can now access detailed 52-week efficacy and safety information, which is crucial for understanding the therapeutic potential and positioning of bimekizumab within the current treatment landscape for this chronic skin condition. This contributes to evidence-based decision-making in patient care for individuals with moderate to severe plaque psoriasis.
Source
The information regarding these trial results was obtained from PubMed, referencing a publication in The Lancet. The article, titled "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blin (Lancet)", was published on 2021-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.